The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 22, 2025
Filed:
Nov. 17, 2016
Applicant:
The Regents of the University of California, Oakland, CA (US);
Inventors:
Varghese John, Los Angeles, CA (US);
Ichiro Nishimura, Venice, CA (US);
Naren Subbiah, Danville, CA (US);
Jesus Campagna, Playa Del Rey, CA (US);
Patricia R. Spilman, Mill Valley, CA (US);
Mohammad Parvez Alam, Los Angeles, CA (US);
Assignee:
The Regents of the University of California, Oakland, CA (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/127 (2025.01); A61K 9/00 (2006.01); A61K 9/107 (2006.01); A61K 9/1272 (2025.01); A61K 31/428 (2006.01); A61K 38/17 (2006.01); A61K 38/50 (2006.01); A61K 47/64 (2017.01); A61K 47/69 (2017.01); A61P 25/14 (2006.01); A61P 25/16 (2006.01); A61P 25/28 (2006.01); A61P 35/00 (2006.01); C12N 15/113 (2010.01); A61K 9/19 (2006.01); A61K 9/70 (2006.01);
U.S. Cl.
CPC ...
A61K 9/127 (2013.01); A61K 9/0014 (2013.01); A61K 9/006 (2013.01); A61K 9/0087 (2013.01); A61K 9/107 (2013.01); A61K 9/1272 (2013.01); A61K 31/428 (2013.01); A61K 38/1709 (2013.01); A61K 38/50 (2013.01); A61K 47/644 (2017.08); A61K 47/6911 (2017.08); A61P 25/14 (2018.01); A61P 25/16 (2018.01); A61P 25/28 (2018.01); A61P 35/00 (2018.01); C12N 15/113 (2013.01); C12Y 305/01 (2013.01); A61K 9/0019 (2013.01); A61K 9/0085 (2013.01); A61K 9/19 (2013.01); A61K 9/70 (2013.01); C12N 2310/141 (2013.01);
Abstract
In various embodiments deformable nano-scale vehicles (DNV) are provided that are useful for the delivery of therapeutic agents. In certain embodiments the DNVs are capable of transdermal delivery and can additionally cross the blood-brain barrier.